Exelixis Cabozantinib Update for Advanced Neuroendocrine Tumors
Exelixis announced that the FDA will discuss its supplemental New Drug Application for cabozantinib, intended to treat advanced pancreatic...
Advancing Immunotherapy: Insights from Ymmunobio CEO
In this discussion, Moe Alsumidaie interviews Peter Schiemann, CEO and Chairman of Ymmunobio, about the company’s innovative approaches to...
Unleashing Patient Insights: Transforming Clinical Trials with Patient Perspectives
At SCOPE Summit Europe 2024, industry leaders gathered to explore the transformative potential of patient perspectives in decentralized clinical...
Privacy Now: Balancing Innovation and Privacy in Genomics
The UK’s Information Commissioner’s Office (ICO) recently issued a critical call for collaboration in genomics, emphasizing the need to...
Exploring Innovative Approaches in Alzheimer’s and Dementia Treatment
In this insightful discussion, we interview Anthony Caggiano, Chief Medical Officer and Lisa Ricciardi, CEO, of Cognition Therapeutics about...
Accelerating ALS Research: Insights from the ALS Association
In this interview, we speak with Dr. Kuldip Dave from the ALS Association to explore their strategic approach to...
Virpax & HHS Partner on NES100 for Pain Relief
Virpax Pharmaceuticals has announced an extension of its research agreement with the National Center for Advancing Translational Sciences (NCATS),...
eClinical Solutions: Top Leader in Everest Group’s Life Sciences D&A Assessment
Everest Group has positioned eClinical Solutions as a Leader in Life Sciences Clinical Data and Analytics Platforms in their...
Omeros Corp. BLA Resubmission Update
Narsoplimab, a first-in-class antibody targeting MASP-2, the effector enzyme of the complement lectin pathway, is under development for hematopoietic...
Fresenius Kabi Aurora Xi 2.0 Software 510(k) Notification
A recent multicenter, prospective randomized controlled clinical trial evaluated a new adaptive nomogram within the Aurora Xi Plasmapheresis System...